TABLE 3.
Effectiveness of WHI-07 gel microemulsion in protecting cats from vaginal FIV transmissiona
| Intravaginal pretreatment | Inoculum (cells) | No. infected/total no. challenged (% of total)
|
P valuee | ||
|---|---|---|---|---|---|
| WBb | VI-RTc | VI-PCRd | |||
| Vehicle | 7 × 106 | 10/10 (100)d | 10/10 (100) | 10/10 (100) | |
| 5% N-9 | 7 × 106 | 6/10 (60) | 6/10 (60) | 6/10 (60) | 0.09 |
| 2% WHI-07 | 7 × 106 | 2/5 (40) | 2/5 (40) | 2/5 (40) | 0.02 |
| 0.25% VDDTC | 7 × 106 | 8/10 (80) | 8/10 (80) | 8/10 (80) | 0.47 |
| 2% WHI-07 + 0.25% VDDTC | 7 × 106 | 1/5 (20) | 1/5 (20) | 1/5 (20) | 0.004 |
a
SPF cats received a vaginal gel (0.4 ml) treatment followed 1 to 2 min later by an intravaginal inoculation of FIVBangston-infected feline lymphoid (FeT-J) cells (7 × 106 cells in 0.2 ml). Systemic FIV infection was monitored at 3, 6, 9, 12, 15, and 18 weeks after intravaginal exposure to chronically FIV-infected feline T cells by the appearance of viral antibodies to FIV Gag proteins by WB and by VI-RT and FIV-specific PCR.
b
WB analysis of FIV Gag proteins p26 and p15 in blood plasma.
c
VI-RT, virus isolation of PBMCs measured by FIV RT activity.
d
VI-PCR, PCR analysis of FIV infection.
e
Vehicle control versus test (Fisher's exact test).